FDA: Actos Raises Risk of Bladder Cancer by 40% for Some Patients
The Food and Drug Administration (FDA) made a disconcerting announcement recently: patients who have taken Actos (pioglitazone) for more than one year face a 40 percent higher likelihood of developing bladder cancer. This announcement came on the heels of a massive study that included more than 193,000 diabetes patients.
Just as troublesome, although the FDA now requires a more informative label, the medical reality is that hundreds of thousands of American type-2 diabetes patients have been relying on Actos (pioglitazone) without knowing the risks they were undertaking. To understand the full scope of problems with pioglitazone, consider that Actos was the 10th best selling drug in 2008 with more than $2.4 billion in sales. The potential for a widespread increase in the incidence of bladder cancer as a result of Actos’ carcinogenic side effects is very real.
Fears Nachawati fights for the rights of Actos (pioglitazone) patients. You deserved a full understanding of Actos’ potential side effects. Having been deprived of full disclosure, you deserve justice for not being fully informed. To start your fight for justice, contact our experienced, expert attorneys today. For a free consultation, call us at 1.866.545.8364 or email email@example.com. We’re ready to fight for you!